Improvement of the Nuclease Resistance and Immunostimulatory Activity of CpG Oligodeoxynucleotides by Conjugation to Sugar-Immobilized Gold Nanoparticles-Reference-Cited by-同舟云学术

Improvement of the Nuclease Resistance and Immunostimulatory Activity of CpG Oligodeoxynucleotides by Conjugation to Sugar-Immobilized Gold Nanoparticles

Published:2024-05-08 Issue:6 Volume:35 Page:804-815
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Murata Koki¹,Harayama Kai¹,Shimoda Mayuko²,Niimura Mayumi²,Wakao Masahiro¹^ORCID,Suda Yasuo³,Moroishi Toshiro²⁴,Shinchi Hiroyuki¹^ORCID

Affiliation:

1. Department of Engineering, Chemistry and Biotechnology program, Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Korimoto, Kagoshima 890-0065, Japan

2. Department of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan

3. Collaborative Research Laboratory on Glyco-nanotechnology, Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Korimoto, Kagoshima 890-0065, Japan

4. Center for Metabolic Regulation of Healthy Aging, Faculty of Life Science, Kumamoto University, Kumamoto 860-8556, Japan

Funder

Kagoshima University

Japan Agency for Medical Research and Development

Japan Society for the Promotion of Science

Takahashi Industrial and Economic Research Foundation

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.4c00145

Reference39 articles.

1. Vaccine adjuvants: mechanisms and platforms

2. Vaccine adjuvants as potential cancer immunotherapeutics

3. Recent progress concerning CpG DNA and its use as a vaccine adjuvant

4. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults

5. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant